Studies of intermittent fasting in people
53 studies gave intermittent fasting to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases body weight-2.7 kg (95% CI -2.9 to -2.4) down: Decreases blood pressure down: Decreases mean glucose | Randomized trial4 weeks | 68 peopleWomenadultsAcross the 16:8 and 5:2 groups with overweight or obesity | Obesity (Silver Spring, Md.), Oct 28, 2026 |
down: Decreases body weight−6.83 ± 4.26 kg (−7.02%) down: Decreases body fat mass−5.38 ± 3.13 kg (−13.61%) down: Decreases soft lean mass−1.44 ± 1.88 kg (−2.68%) | Trial62-day | 35 people20 males (57.10%) and 15 females (42.90%)average age of 36.23 ± 8.98 yearsIndividuals with obesity in China | Frontiers in nutrition, Sep 9, 2026 |
no change: Has no effect on thigh muscle area no change: Has no effect on intermuscular adipose tissue | Randomized triala month-long | 66 peopleGeneral population | Clinical radiology, Aug 22, 2026 |
down: Decreases body mass | Randomized trial4 weeks | 80 peopleMenyoung adultAlternate-day fasting protocol | Preprints.org, Aug 19, 2026 |
down: Decreases diabetes medication burden67% up: Increases type 2 diabetes remission14% | Randomized trial12 months | 57 peoplePatient cohorts | ADA Scientific Sessions 2026 abstract, Jun 5, 2026 |
down: Decreases body weight down: Decreases fat mass down: Decreases fat-free mass | Review of trials | 1,833 people pooled<30 yearsGeneral population; Midlife adults | Nutrients, Jun 3, 2026 |
down: Decreases body weight-1.025 kg (95% CI: -0.09 to -1.96 kg; p = 0.03) | Randomized trial12 weeks | 20 peoplemean age 53 ± 9.5 yearsMidlife adults; Patient cohorts | Clinical nutrition ESPEN, May 4, 2026 |
no change: Has no effect on remissionOR 1.5, 95% CI: 0.6–4.3 | Randomized trial12 weeks | 120 people50.0 years (SD = 7.7)Adults aged 18–60 years with less than 5 years duration of type 2 diabetes diagnosis | Endocrinology, diabetes & metabolism, Apr 12, 2026 |
down: Decreases body weighttwofold more weight and fat loss no change: Has no effect on muscle strength no change: Has no effect on testosterone | Randomized trial8 weeks | 20 peopleMen20-30Obese males undergoing resistance training | Journal of obesity, Feb 19, 2026 |
| Trial16-h | In patients receiving neoadjuvant immunotherapy | Cell metabolism, Feb 19, 2026 | |
down: Decreases body weight-1.6 kg (95% CI -2.5 to -0.8) down: Decreases muscle mass-1.3 kg (95% CI -2.5 to -0.2) no change: Has no effect on fat mass-0.1 kg (95% CI -1.3 to 1.4) | Randomized trial12 weeks | 57 peopleBothPatient cohorts | JMIR mHealth and uHealth, Jan 26, 2026 |
| Trial12 months | 30 people15 men and 15 women20–40 yearsIndividuals with obesity | Medicina (Kaunas, Lithuania), Jan 25, 2026 | |
down: Decreases body weight107.3 ± 17.5 kg to 100.5 ± 15.2 kg, p < 0.001 | Treated cohort3 months | 26 peopleBothmean age 60 yearsMidlife adults; Older adults; type 2 diabetes and overweight or obesity | Clinical nutrition ESPEN, Jan 24, 2026 |
down: Decreases HbA1c−0.50 vs −0.20 down: Decreases body weight-6.51% vs -4.41% down: Decreases body fat mass-9.39% vs -5.32% | Randomized trial12 weeks | 125 peopleaged 21 to 60 yearsAdults aged 21 to 60 years, diagnosed with type 2 DM, and classified as obese | European journal of clinical nutrition, Jan 7, 2026 |
down: Decreases body weight | Randomized trial6 months | 10 peopleMenaverage age of 65.9 (SD 8.45) yearsOlder adults; in prostate cancer patients on active surveillance | Translational behavioral medicine, Jan 1, 2026 |
down: Decreases body weight | Trialthree months | Women35.5-36.3 yearsObese women | La Tunisie medicale, Dec 15, 2025 |
down: Decreases fasting blood glucose-2.3 mmol/L [SD 1.51 mmol/L] down: Decreases triglyceride-1.139 mmol/L [SD 1.335 mmol/L] up: Increases Matsuda Index80.23 [SD 70.69] | Randomized trial16 weeks | 63 peopleBothaverage age 36.8 yearsObesity with type 2 diabetes | ENDO 2025 abstract, Oct 22, 2025 |
down: Decreases body weightp = 0.012 for young, p = 0.011 for middle-aged down: Decreases total cholesterolp = 0.004 for young, p = 0.0024 for middle-aged no change: Has no effect on triglyceride | Randomized trialfive months | 40 peopleMen23–28 and 46–59 yearsMidlife adults | Nutrition and health, Oct 15, 2025 |
down: Decreases fat mass down: Decreases muscle mass | Randomized trial6 months | 23 peopleIn overweight and class 1 obese patients | Acta endocrinologica (Bucharest, Romania : 2005), Oct 3, 2025 |
down: Decreases metabolomic age−6.58 years/month (95% CI: −12.92, −0.23) | Randomized trial8-week | 31 peoplePatients with relapsing-remitting multiple sclerosis | Annals of neurology, Sep 19, 2025 |
no change: Has no effect on cardiometabolic health | Randomized trial3 months | 34 people63.6 ± 9.2 years oldOlder adults; type 2 diabetes | Diabetes, obesity & metabolism, Sep 18, 2025 |
up: Improves cardiorespiratory fitness down: Decreases epithelial DNA methylation biomarkers of cancer risk up: Increases ImmuneAge | Trialsix months | 114 peopleWomenPostmenopausal women; BMI 25-35 | bioRxiv (Cold Spring Harbor Laboratory), Sep 4, 2025 |
| Trial6 months | 156 peopleWomen30-60 yearsMidlife adults; highly compliant participants | bioRxiv (Cold Spring Harbor Laboratory), Sep 1, 2025 | |
no change: Has no effect on new T2 lesions down: Decreases NEFL down: Decreases depressive symptoms | Randomized trial18 months | 105 peoplePatients with relapsing-remitting multiple sclerosis | BMC nutrition, Aug 20, 2025 |
down: Decreases body weight down: Decreases fasting blood glucose | Trial24 weeks | 31 peoplePatient cohorts | Nutrition research and practice, Jul 25, 2025 |
down: Decreases binge eating no change: Has no effect on leptin | Randomized trial12 months | 165 peopleBoth18–60 yearsMidlife adults; Patient cohorts | Nutrients, Jul 21, 2025 |
no change: Has no effect on mTOR no change: Has no effect on metabolic age | Trial20 days | 24 peoplewomen21.29 ± 1.76 yearsYoung obese women | Nutrients, May 16, 2025 |
| Randomized trial12 months | 165 peopleBoth18–60 yearsMidlife adults; Patient cohorts | Annals of internal medicine, Mar 31, 2025 | |
up: Improves cognitive functionCohen’s d = 0.58 down: Decreases insomniaCohen’s d = 0.52 | Trial8-week | 20 peoplepredominantly female (95%)mean age of 69.7 years oldOlder adults with self-reported memory decline | Journal of clinical and translational science, Dec 12, 2024 |
down: Decreases HOMA-IR−0.77 ± 0.81 vs −0.07 ± 1.06 no change: Has no effect on HOMA-IR−0.69 ± 0.75 vs −0.42 ± 0.92 no change: Has no effect on body weight−1.74 ± 4.81 kg vs. 0.21 ± 3.50 kg | Randomized trial26 weeks | 68 people21-70 yearsMidlife adults; in subjects with higher baseline HGH | npj metabolic health and disease, Oct 3, 2024 |
down: Lowers the risk of metabolic-associated fatty liver disease33.3% vs. 63.0% no change: Has no effect on body weight | Randomized trial12-week period | 60 people31 ± 9 yearsParticipants recruited from the fatty liver obesity diagnosis and treatment center | Frontiers in nutrition, Aug 20, 2024 |
down: Decreases brain-age-gap estimate-2.63 vs -2.42 years up: Improves executive function | Randomized trial8 weeks | 46 people60% of participants were femalesmean age 63.2 yearsIndividuals aged 55–70 years with overweight/obesity and insulin resistance who were cognitively normal | Cell metabolism, Jun 19, 2024 |
down: Decreases ICHRONp = 0.035 down: Decreases HOMA-IRmedian HOMA-IR change: intermittent fasting, −0.95 [interquartile range (IQR): −1.71, −0.61] vs. ad libitum controls, 0.05 [IQR: −0.44, 0.47] | Randomized trial26 weeks | 69 peoplealmost 65% of subjects were femaleaveraged 49.4 yearsIndividuals with modest elevation of low-density lipoprotein cholesterol and one or more factors of the metabolic syndrome | International journal of cardiology. Cardiovascular risk and prevention, Sep 11, 2023 |
up: Increases dehydroepiandrosterone+11% MESOR no change: Has no effect on dehydroepiandrosterone no change: Has no effect on cortisol | Trial24-h | 49 people25 women and 24 menmean age 48.6 ± 12.8 yearsPatients with obesity | Frontiers in nutrition, Feb 6, 2023 |
down: Decreases body weight no change: Has no effect on C-reactive protein up: Improves oral glucose tolerance test-derived insulin sensitivity index | Randomized trialsix-month | 50 people30 women, 20 menaged 30–65 yHealthy, overweight, or mildly obese (BMI 24.0–35.0 kg/m2), weight-stable (<2 kg weight change in the previous six months) men and women | Aging biology, Jan 1, 2023 |
up: Increases GDF-155% more than CR70 down: Decreases body weightgreater weight loss than CR70 | Randomized trial8 weeks | WomenPatient cohorts | Obesity research & clinical practice, Dec 9, 2022 |
down: Decreases body weight-1.8 kg (-2.8%, p < 0.001) down: Decreases energy intakemedian 1288.0 vs 1751.5 kcal, p < 0.001 | Trial28 days | 52 peopleBoth44 ± 11.2 yrsMidlife adults | Clinical nutrition ESPEN, Aug 17, 2022 |
down: Decreases effector memory T cell-4.87% (95% CI: -8.59%, -1.15%) up: Increases naïve T cells10.11% (95% CI: 3.30, 16.92%) down: Decreases Th1 cells-4.26% (95% CI: -7.11%, -1.40%) | Randomized trial8 weeks | 36 people81% female37.4 ± 7.4 yearsPeople with multiple sclerosis aged 18 to 50 | EBioMedicine, Jul 8, 2022 |
down: Decreases body weightP < .001 no change: Has no effect on mood no change: Has no effect on cognitive function | Randomized trial8 weeks | 46 peopleWomenmean [SD] age 50 [9] yearsMidlife adults; women with overweight or obesity | Nutrition research (New York, N.Y.), Jun 24, 2021 |
down: Decreases HbA1c43 ± 2.7 to 41 ± 2.3 mmol/mol down: Decreases body weightaverage 5% weight loss | Randomized trial12 weeks | 26 peoplemean 52 yearsMidlife adults; all participants, probiotic and placebo groups combined | Nutrients, Nov 17, 2020 |